Walter Berger

TL;DR: FGF/FGFR inhibitors might represent a novel component for combined NSCLC therapy approaches because of their role in therapy resistance against not only classical chemotherapy but also novel targeted anti-NSCLC agents like inhibitors of the epidermal growth factor receptor (EGFR).

TL;DR: Proof varying efficacy of epigenetically active drugs in high-risk EPN subgroups, in particular EZH2 inhibition in ZFTA-RELA cell models is proved.

TL;DR: A central role of defined RTK signaling modules in the malignant phenotype of CNS-BCOR-ITD and tumors harboring BCOR alterations and RTK hyperactivation is uncovered and elucidate their potential as therapeutic targets.

TL;DR: The ITCC-P4 sustainable platform represents a validated and powerful tool to investigate the biology of pediatric cancer based on the establishment, characterization, and preclinical testing of patient-derived xenograft (PDX) models, ultimately envisaged to contribute the development of innovative therapeutic options for childhood cancer patients as mentioned in this paper .

TL;DR: In this article, the authors proposed a 4-anilinoquinazoline tyrosine kinase inhibitor (4-ANILINQINI) for hyperproliferative diseases such as cancer.